Interleukin 4 responses in acute leukaemia patients with severe chemotherapy-induced leucopenia

European Journal of Haematology

Volumn 59, Issue 5, 1997, Pages 269-276

  Bruserud, O ^a,b   Ulvestad, E ^a   Halstensen, A ^a   Berentsen, S ^a   Bergheim, J ^a   Nesthus, I ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute leukaemia; Chemotherapy; Interleukin 4

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; INTERLEUKIN 4; MITOXANTRONE; PREDNISONE; TIOGUANINE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; NEUTROPENIA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0030730035     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1997.tb01686.x     Document Type: Article

References (15)

1. MEYER RJ, DAVIES RB, SCHIFFER CA, et al. Intensive postremission therapy in adults with acute myeloid leukemia. N Engl J Med 1994: 331: 896-903.
2. HOELTZER D.. Treatment of acute lymphoblastic leukaemia. Semin Oncol 1994: 31: 1-15.
3. BRUSERUD Ø, PEEN E, HALSTENSEN A, SOLBERG CO. Serum levels of adhesion molecules and cytokines in patients with acute leukaemia. Leuk Lymph 1996: 23: 423-430.
4. CHRISTMAN JW. Potential treatment of sepsis syndrome with cytokine-specific agents. Chest 1992: 102: 613-617.
5. PAWELEC, G. Immune surveillance of leukaemia: rationale for immunotherapy. Haemat Rev 1994: 8: 123-147.
6. VAN DER MEER JWM. Defects in host defence mechanisms. In: RUBIN RH, YOUNG LS, eds. Clinical approach to infection in the compromised host, 3rd edn. New York: Plenum, 1994.
7. + T cell clones derived early after allogeneic bone marrow transplantation: studies in patients with chronic myelogenous leukaemia. Eur J Haematol 1992: 48: 221-227.
8. + T cell clones derived early after allogeneic bone marrow transplantation. Scand J Immunol 1993: 38: 65-74.
9. OSTERMANN H, ROTHENBURGER M, MESTERS RM, VAN DE Loo J, KIENAST J. Cytokine response to infection in patients with acute myelogenous leukemia following intensive chemotherapy. Br J Haematol 1994: 88: 332-337.
10. RINTALA E, PULKKI K, MERTSOLA J, NEVALAINEN T, NIKOSKELAINEN J. Endotoxin, interleukin 6 and phospholipase-A2 as markers of sepsis in patients with hematological malignancies. Scand J Infect Dis 1995: 27: 39-43.
11. STEINSHAMN S, BREKKE O-L, WAAGE A. Soluble tumour necrosis factor receptors, tumour necrosis factor and interleukin 6 in serum in granulocytopenic patients with fever. Br J Haematol 1995: 89: 719-724.
12. PAUL WE. Interleukin 4: a prototypic immunoregulatory lymphokine. Blood 1991: 77: 1859-1870.
13. CARUSO A, LICENZIATI S, CORULLI M, et al. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometri 1997: 27: 71-76.
14. FANSLOW WC, CUFFORD KN, PARK LS, et al. Regulation of alloreactivity in vivo by IL4 and soluble IL4-receptors. J Immunol 1991: 147: 535-540.
15. O'FLYNN K, RUSSUL-SAIB M, ANDO I, WALLACE DL, BEVERLY PCL. Different pathways of human T cell activation revealed by PHA-P and PHA-M. Immunology 1986: 57: 55-60.